Market Overview

UPDATE: Piper Jaffray Upgrades Myriad Genetics to Overweight on Reimbursement Strategy Confidence

Share:
Related MYGN
JPMorgan Checks In On Myriad Genetics Following 30% Rally
Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7%

Piper Jaffray raised its rating on Myriad Genetics (NASDAQ: MYGN) from Neutral to Overweight and increased its price target from $28 to $35.

Piper Jaffray commented, "Management expressed a high level of confidence in their reimbursement strategy, citing multiple layers of stability and a tight range around their median rates (specifically Medicaid and managed care). Additionally, we believe Myriad's longer-term strategy to combat generic BRCAnalysis tests by expanding its panel beyond BRCA 1/2, capturing a larger percentage of heredity cancer has shades of the old, but successful, intellectual property HPV argument. Based on our diligence, management's comments and an updated DCF scenario analysis, we see the risk premium the market currently ascribes as excessive."

Myriad Genetics closed at $26.95 on Friday.

Latest Ratings for MYGN

DateFirmActionFromTo
Feb 2017Ladenburg ThalmannUpgradesSellNeutral
Jan 2017Deutsche BankInitiates Coverage OnSell
Nov 2016Stephens & Co.DowngradesOverweightEqual-Weight

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!